Get the Stockscreener App
2.32
2.65%
0.06
After Hours:
2.23
-0.09
-3.88%
Equillium Inc stock is traded at $2.32, with a volume of 269.64K.
It is up +2.65% in the last 24 hours and up +7.41% over the past month.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
See More
Previous Close:
$2.26
Open:
$2.31
24h Volume:
269.64K
Relative Volume:
0.64
Market Cap:
$146.69M
Revenue:
$4.39M
Net Income/Loss:
$-22.40M
P/E Ratio:
-4.5508
EPS:
-0.5098
Net Cash Flow:
$-22.79M
1W Performance:
+31.44%
1M Performance:
+7.41%
6M Performance:
+127.45%
1Y Performance:
+471.43%
1-Day Range:
$2.2081
$2.35
1-Week Range:
$1.78
$2.39
52-Week Range:
$0.27
$2.70
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
2.32 | 142.89M | 4.39M | -22.40M | -22.79M | -0.5098 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-26 | Initiated | Oppenheimer | Outperform |
| Apr-16-26 | Initiated | B. Riley Securities | Buy |
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Apr-07-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Mar-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
View All
Equillium Inc Stock (EQ) Latest News
EQ Stock Chart | EQUILLIUM INC (NASDAQ:EQ) - ChartMill
Equillium to Host Virtual Investor Event to Share New - GlobeNewswire
ADAR1 entities hold ~9–10% of Equillium (EQ) as of Mar 31, 2026 - Stock Titan
Decheng Capital & Xiangmin Cui report 5.73M EQ shares (EQ) - Stock Titan
Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Equillium: Compliance, Operational and Market Risks Cloud Long-Term Outlook for Shareholders - TipRanks
TradingKey - TradingKey
Equillium, Inc. Stock 12‑Month Price Target Cut to $6.38, Implies 176% Upside - TradingView
Equillium (EQ) Advances Research on EQ504 for Immune Modulation - GuruFocus
Is Equillium (EQ) 2210.0% Overvalued After Q1 2026 Earnings? GF - GuruFocus
Equillium Inc. (NASDAQ:EQ) Reports Narrower Q1 Loss But Slight EPS Miss as EQ504 Study Timeline Confirmed - ChartMill
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Equillium (NASDAQ: EQ) trims Q1 2026 loss, raises $35M and funds runway into 2029 - Stock Titan
Equillium (NASDAQ: EQ) trims Q1 2026 loss and extends cash runway into 2029 - Stock Titan
Number of shareholders of Equillium, Inc. – NASDAQ:EQ - TradingView
Number of shareholders of Equillium, Inc. – DUS:0FY - TradingView
Equillium Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
EQ (Equillium) EPS beats by 35% but shares fall 1.4% as investors eye pipeline milestones over near-term losses.Trending Volume Leaders - newser.com
What separates Equillium (EQ) from the pack? (-1.38%) 2026-05-07Momentum Investing - Newser
Aberdeen Group (NASDAQ: EQ) shows 3.35M-share stake in Equillium - Stock Titan
Should you add Equillium (EQ) to your watchlist today? (Bearish Momentum) 2026-05-05High Interest Stocks - Newser
Equillium, Inc. (NASDAQ:EQ) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Equillium, Inc. Grants Inducement Stock Options to New Employees Under 2024 Inducement Plan - Quiver Quantitative
Two new Equillium hires receive options for 800,000 shares - Stock Titan
B Riley Securities initiates coverage of Equillium (EQ) with buy recommendation - MSN
Equillium (EQ) price target increased by 120.00% to 5.61 - MSN
Oppenheimer Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $7 - Moomoo
Equillium (NASDAQ:EQ) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage on Equillium With Outperform Rating, $7 Price Target - marketscreener.com
Oppenheimer initiates Equillium stock with Outperform on UC drug By Investing.com - Investing.com Australia
Oppenheimer initiates Equillium stock with Outperform on UC drug - Investing.com
Equillium initiated with an Outperform at Oppenheimer - TipRanks
Is It Stable or Volatile | Equillium Inc. Posts 35.3% EPS Beat, Narrower Net Loss Vs EstimatesElite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event - The Manila Times
EQ Reiterated by Roth Capital -- Price Target Maintained at $12 - GuruFocus
Equillium (EQ) price target increased by 10.71% to 7.90 - MSN
Roth Mkm Reiterates Buy Rating for Equillium (NASDAQ:EQ) - MarketBeat
[EFFECT] Equillium, Inc. SEC Filing - Stock Titan
Here’s what Roth Capital thinks of Equillium (EQ) stock - MSN
EQ Upgraded by B. Riley Securities -- Price Target Announced at $6.00 - GuruFocus
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Equillium Inc Stock (EQ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Mar 13 '26 |
Sale |
2.50 |
120,312 |
300,816 |
62,586 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):